ABSTRACT
Objective To explore the expression of miR-223-3p in the plasma of patients with diabetic kidney disease and its clinical significance. Methods The expression levels of plasma miR-223-3p in normoalbuminuric group (DM) , microoalbuminuria group (Micro-DKD) , macroalbuminuria group (Macro-DKD) and healthy controls were measured by quantitative real-time polymerase chain reaction (qRT-PCR) . To analysis the relationship with clinical pathological parameters,target genes of miR-223-3p were predicted with bioinformatics software. Results The levels of miR-223-3p in the plasma of the remaining three groups were significantly lower than those in the healthy controls (P＜0.001), and the decrease was positively correlated with the severity of the disease. The potential target genes of miR-223-3p identified by bioinformatics softwares include IL6ST and PRKCE. Conclusion The expressionof miR-223-3pin diabetic kidney disease (DKD) patients' plasma decreased and was positively correlated with the severity of the disease. It may play an important role in the development and progression of diabetic kidney disease through its target genes.
ABSTRACT
<p><b>OBJECTIVE</b>To study the change of intestinal mucosa barrier in chronic severe hepatitis B patients and clinical intervention.</p><p><b>METHOD</b>(1) 30 normal healthy controls and 60 chronic severe hepatitis B patients were enrolled in this study. The change of intestinal permeability was determined by urine lactulose/ mannitol ratio (L/M), and the serum diamine oxidase (DAO) was measured. (2) 60 chronic severe hepatitis B patients were randomly divided into two groups: the control group and the treated group, each group has 30 cases. Patients in the control group received standard treatment for 2 weeks, however, in addition to standard treatment, patients in the treated group also received glutamine 10g tid. Endotoxin (ET), DAO and L/M were compared between the two group.</p><p><b>RESULTS</b>(1) Compared to healthy controls, the level of L/M and DAO was significantly increased in chronic severe hepatitis B patients (t = 2.762, P less than 0.01 or t = 6.326, P less than 0.01). (2) Compared to the control group, ET, DAO and L/M were significantly lower 2 weeks after treatment (F = 11.662, P less than 0.01; F = 12.699, P less than 0.01; F = 19.981, P less than 0.01).</p><p><b>CONCLUSION</b>(1) There is an early intestinal mucosa barrier damage in chronic severe hepatitis B patients. (2) Compared to standard treatment, adding glutamine can reverse intestinal mucosa barrier damage.</p>
